Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pharmacyclics, Inc.    PCYC

No quotes available
-- USD   0.00%
01/07 PHARMACYCLICS : AbbVie Announces Submission of a Supplemental New Dr..
01/07 PHARMACYCLICS : Ibrutinib (IMBRUVICA«) Combination Data Show Promise..
01/07 PHARMACYCLICS : IMBRUVICA« (ibrutinib) Awarded Prix Galien 2015 Best..
SummaryQuotesNewsCalendarCompany 
News SummaryMost relevantAll newsSector news 

Pharmacyclics Inks Agreement With Novo Nordisk for Molecule Inhibitor

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/10/2012 | 12:25am CEST
   By Kristin Jones 
 

Pharmacyclics Inc. (>> Pharmacyclics, Inc.) has inked an agreement with Novo Nordisk A/S (NVO, NOVO-B.KO) giving the Danish insulin producer rights to certain uses of its Factor VIIa molecule inhibitor, according to a regulatory filing.

Pharmacyclics shares rose 3.75% to $67.20 in after-hours trading. Through the close, the stock had more than doubled in the past six months.

Under the terms of the agreement, Novo Nordisk will acquire the world-wide rights to PCI-27483 for specific noncancer-related uses. The Danish company plans to use it as an excipient in an unnamed product within its biopharmaceutical unit.

An excipient is generally an inactive ingredient used to carry or to add a certain consistency to a drug.

Pharmacyclics has been developing PCI-27483 to inhibit the intracellular signaling involved in tumor growth and to thwart the blood clots that afflict some cancer patients.

The biopharmaceutical company expects to receive an upfront payment of $5 million, as well as up to $55 million based on the achievement of certain development, regulatory and sales milestones. It also will receive royalties on sales of Novo Nordisk products that use PCI-27483.

Novo Nordisk's American depositary shares closed Tuesday at $161.38 and were unchanged after hours. The ADS are up 40% so far this year.

Write to Kristin Jones at kristin.jones@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pharmacyclics, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on PHARMACYCLICS, INC.
01/07 PHARMACYCLICS : Ibrutinib (IMBRUVICA«) Combination Data Show Promise in Patients..
01/07 PHARMACYCLICS : IMBRUVICA« (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceuti..
01/07 PHARMACYCLICS : AbbVie’s Commitment to Oncology Demonstrated at the 57th A..
01/07 PHARMACYCLICS : AbbVie Announces Submission of a Supplemental New Drug Applicati..
01/07 PHARMACYCLICS : IMBRUVICA« (ibrutinib) Now Approved to Treat Waldenström’s..
01/07 PHARMACYCLICS : Ibrutinib (IMBRUVICA«) Improved Survival for Treatment–Naï..
01/07 PHARMACYCLICS : Ibrutinib (IMBRUVICA«) Improved Survival for Treatment–Naï..
2015 PHARMACYCLICS : Updates on Ibrutinib (IMBRUVICA) Phase Ib/II Data
2015 PHARMACYCLICS : Updates on Phase III RESONATE Data
2015 Abbvie completes $21 billion buyout of Pharmacyclics
Advertisement